



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Frontiers Production Office
✉ production.office@frontiersin.org

RECEIVED 22 July 2025
ACCEPTED 22 July 2025
PUBLISHED 05 August 2025

CITATION
Frontiers Production Office (2025)
Correction: The impact of sarcopenia on
prognosis and fruquintinib efficacy in
advanced colorectal cancer: a retrospective
and mendelian randomization study.
Front. Immunol. 16:1671178.
doi: 10.3389/fimmu.2025.1671178

COPYRIGHT
© 2025 Frontiers Production Office. This is an
open-access article distributed under the terms
of the [Creative Commons Attribution License](#)
(CC BY). The use, distribution or reproduction
in other forums is permitted, provided the
original author(s) and the copyright owner(s)
are credited and that the original publication
in this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Correction: The impact of sarcopenia on prognosis and fruquintinib efficacy in advanced colorectal cancer: a retrospective and mendelian randomization study

Frontiers Production Office*

Frontiers Media SA, Lausanne, Switzerland

KEYWORDS

sarcopenia, immune, nutrition, advanced colorectal cancer, fruquintinib, mendelian randomization study

A Correction on
















The impact of sarcopenia on prognosis and fruquintinib efficacy in advanced colorectal cancer: a retrospective and mendelian randomization study

By Wang Y, Meilu D, Qi S, Yufei T, Song G, Susu H, Haotian W, Tingting Z, Chao W, Fenggang H and Xiaoling Y (2025) *Front. Immunol.* 16:1582308. doi: 10.3389/fimmu.2025.1582308

Due to a production mistake, there was a mistake in **Table 3** and **Table 5** as published. The tables were swapped. The corrected **Table 3** and **Table 5** appear below.













The publisher apologizes for the error and the original version of this article has been updated.

TABLE 3 MR results of exposure factors and outcomes (left hand grip strength).

exposure	outcome	method	nsnp	pval		OR(95% CI)	pleio_P
FLT4	Hand grip strength (left)	IVW	4	0.002		1.013 (1.005 to 1.021)	0.480
CA2		IVW	33	<0.001		1.007 (1.003 to 1.011)	0.826
ZAP70		IVW	12	<0.001		1.013 (1.008 to 1.019)	0.228
HDAC1		IVW	4	0.047		1.013 (1.000 to 1.026)	0.641
ADORA2A		IVW	3	0.001		1.017 (1.007 to 1.028)	0.845
SLC27A1		IVW	7	0.020		1.012 (1.002 to 1.021)	0.338
CDK7		IVW	3	0.037		1.017 (1.001 to 1.033)	0.337
CTSL		IVW	12	0.040		1.005 (1.000 to 1.009)	0.553
CTSK		IVW	26	<0.001		1.006 (1.003 to 1.009)	0.182
CTSS		IVW	27	<0.001		1.009 (1.007 to 1.012)	0.461
ADORA1		IVW	4	0.037		1.005 (1.000 to 1.009)	0.684
SYK		IVW	17	0.037		1.004 (1.000 to 1.009)	0.284
IMPDH2		IVW	12	<0.001		1.041 (1.031 to 1.051)	0.056
IRAK4		IVW	8	0.028		1.008 (1.001 to 1.015)	0.430
MTOR		IVW	4	0.003		1.009 (1.003 to 1.015)	0.737

pavl: Significance; OR, Odds ratio, with the 95% confidence interval of the odds ratio in parentheses; pleio_P: Test for horizontal pleiotropy.

TABLE 5 MR results of exposure factors and outcomes (limb muscle mass).

exposure	outcome	method	nsnp	pval		OR(95% CI)	pleio_P
BAD	Appendicular lean mass	IVW	3	0.005		1.033 (1.010 to 1.056)	0.782
FLT4		IVW	4	0.013		1.013 (1.003 to 1.024)	0.497
CDC7		IVW	23	<0.001		1.013 (1.008 to 1.017)	0.125
PDE8B		IVW	7	<0.001		1.026 (1.016 to 1.037)	0.292
ZAP70		IVW	13	0.004		1.015 (1.005 to 1.025)	0.749
PTK2B		IVW	16	<0.001		1.010 (1.005 to 1.015)	0.189
CDK7		IVW	3	0.007		1.027 (1.007 to 1.047)	0.305
CTSL		IVW	12	0.015		1.007 (1.001 to 1.013)	0.402
CTSK		IVW	26	<0.001		1.021 (1.016 to 1.027)	0.975
CTSS		IVW	29	<0.001		1.036 (1.027 to 1.045)	0.116
FNTA		IVW	8	0.006		1.024 (1.007 to 1.042)	0.265
MTOR		IVW	4	<0.001		1.064 (1.056 to 1.072)	0.913

pavl: Significance; OR, Odds ratio, with the 95% confidence interval of the odds ratio in parentheses; pleio_P: Test for horizontal pleiotropy.